Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
作者信息
Chan Wei Yee, Howells Lara, Wilson William, Sanchez Emilie, Ainley Louise, Chavda Selina J, Dowling Emma, Correia Nuno, Lecat Catherine S Y, McMillan Annabel, Wisniowski Brendan, Mahmood Shameem, Papanikolaou Xenofon, Lee Lydia, Sive Jonathan, Kyriakou Charalampia, Wechalekar Ashutosh, Popat Rakesh, Rabin Neil, Nastouli Eleni, Yong Kwee L, Xu Ke
机构信息
Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Research Department of Haematology, UCL Cancer Institute, London, UK.
出版信息
Br J Haematol. 2022 Feb;196(3):e21-e26. doi: 10.1111/bjh.17864. Epub 2021 Oct 10.
Abstract
摘要
相似文献
1
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.浆细胞疾病患者接种第一剂和第二剂BNT162b2 mRNA或ChAdOx1 nCoV-19新冠疫苗后的血清学反应：宿主和疾病因素的影响
Br J Haematol. 2022 Feb;196(3):e21-e26. doi: 10.1111/bjh.17864. Epub 2021 Oct 10.
2
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
3
Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
4
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.评价两种结合抗体检测试剂盒和中和抗体检测试剂盒在评估 SARS-CoV-2 疫苗接种后的体液免疫应答中的应用。
Microbiol Spectr. 2021 Dec 22;9(3):e0120221. doi: 10.1128/Spectrum.01202-21. Epub 2021 Nov 24.
5
Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.在三个月期间内对 ChAdOx1 nCoV-19 和 BNT162b2 疫苗以及对自然发生的 2019 年冠状病毒病感染的免疫应答。
J Infect Dis. 2022 Mar 2;225(5):777-784. doi: 10.1093/infdis/jiab579.
6
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.针对 SARS-CoV-2 的三种不同疫苗加强免疫后的抗体反应动力学。
Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.
7
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.在英国（ComFluCOV）成年人中同时接种 COVID-19 疫苗（ChAdOx1 或 BNT162b2）和季节性流感疫苗的安全性和免疫原性：一项多中心、随机、对照、4 期临床试验。
Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.
8
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.尽管接种了mRNA疫苗加强针，但仍出现了新冠病毒奥密克戎变异株突破性感染。
Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.
9
Comparative study of neutralizing antibodies titers in response to different types of COVID-19 vaccines among a group of egyptian healthcare workers.埃及医护人员群体中针对不同类型 COVID-19 疫苗的中和抗体滴度的比较研究。
Virol J. 2024 Nov 5;21(1):277. doi: 10.1186/s12985-024-02546-0.
10
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.墨西哥海军人员中两剂BNT162b2 mRNA新冠疫苗加一剂ChAdOx1-S加强针的免疫原性
Viruses. 2024 Apr 1;16(4):551. doi: 10.3390/v16040551.
引用本文的文献
1
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.系统评价和荟萃分析：多发性骨髓瘤患者对 COVID-19 疫苗接种的免疫反应。
BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.
2
Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19.新型冠状病毒肺炎（COVID-19）多发性骨髓瘤患者的临床特征及风险分层
Cancers (Basel). 2023 Jul 13;15(14):3598. doi: 10.3390/cancers15143598.
3
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
4
Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.新冠病毒疫苗在恶性疾病患者中的有效性和安全性
Vaccines (Basel). 2023 Feb 20;11(2):486. doi: 10.3390/vaccines11020486.
5
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
6
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance.意义未明的单克隆丙种球蛋白病患者全程接种疫苗前后的新型冠状病毒2型感染发生率及转归
Hemasphere. 2022 Nov 9;6(12):e800. doi: 10.1097/HS9.0000000000000800. eCollection 2022 Dec.
7
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.
8
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.COVID-19 疫苗在血液系统恶性肿瘤患者中的有效性、免疫原性和安全性：系统评价。
Blood Cancer J. 2022 May 31;12(5):86. doi: 10.1038/s41408-022-00684-8.
9
Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.浆细胞疾病患者感染新型冠状病毒突破性感染的风险增加。
Blood. 2022 Aug 18;140(7):782-785. doi: 10.1182/blood.2022016317.
10
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.癌症患者的 COVID-19 疫苗：免疫原性、疗效和安全性。
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11.
本文引用的文献
1
Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people.老年人延长间隔同源双剂量接种BNT162b2或ChAdOx1疫苗后的免疫原性差异
Immun Ageing. 2021 Aug 20;18(1):34. doi: 10.1186/s12979-021-00246-9.
2
Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths.在 70 岁以上未感染的人群中，有 4%存在中和 I 型干扰素的自身抗体，占 COVID-19 死亡人数的 20%。
Sci Immunol. 2021 Aug 19;6(62). doi: 10.1126/sciimmunol.abl4340.
3
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.接受免疫调节治疗的浆细胞疾病患者无症状感染新型冠状病毒2后抗体反应的发展情况。
Br J Haematol. 2021 Sep;194(5):857-861. doi: 10.1111/bjh.17441. Epub 2021 Jul 29.
4
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
5
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
6
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.多发性骨髓瘤患者对 BNT162b2 mRNA COVID19 疫苗的体液反应率和反应预测因子。
Br J Haematol. 2021 Oct;195(2):186-193. doi: 10.1111/bjh.17608. Epub 2021 Jul 1.
7
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
8
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.癌症患者接种一剂与两剂新冠疫苗BNT162b2的安全性和免疫原性：一项前瞻性观察研究的中期分析
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
9
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
10
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
Zotero 插件